Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)332.29K

Market Cap

¥10.95B

Enterprise Value¥9.93B

Total Cash (Recent Filing)¥2.85B

Total Debt (Recent Filing)¥727.12M

Price to Earnings (P/E)―

Beta1.00

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding36,034,100

10 Day Avg. Volume566,500

30 Day Avg. Volume332,290

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)10.64

Price to Sales (P/S)79.85

P/FCF Ratio-74.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsConsistently very high gross margins (77%–90%) indicate strong product-level economics and pricing power. Over months this supports leverage of selling, general and R&D spend into scalable profit recovery when revenue stabilizes, improving long-term cash conversion potential.

Manageable LeverageRecent debt-to-equity near 0.24–0.39 suggests low-to-moderate leverage versus historical peaks. That capital structure reduces near-term refinancing pressure, preserves financial flexibility during revenue weakness, and supports funded R&D or partnership deals without immediate solvency risk.

Demonstrated Cash Generation (2025)The firm produced positive operating and free cash flow in 2025, demonstrating the business can convert revenue into cash under favorable conditions. This indicates a potential structural ability to be cash-generative if revenue volatility is reduced and cost discipline is maintained.

Bears Say

Persistent UnprofitabilityConsistent negative ROE and extremely deep net losses (net margin ~-241% in 2026) show the company fails to cover operating costs. Structurally unprofitable operations increase burn, limit reinvestment capacity, and require sustained revenue improvement or major cost restructuring to reach durability.

Severe Revenue VolatilityA ~67% YoY revenue drop in 2026 after a stronger 2025 highlights material top-line instability. For a biotech/pharma company, such swings impair planning for R&D, commercial expansion and partnerships, reduce predictability of cash flows, and hinder multi-quarter recovery execution.

Inconsistent Cash GenerationRecurrent negative free cash flow across multiple years and a reversion to negative FCF in 2026 imply recurring funding needs. That pattern raises refinancing or dilution risk, constrains sustained R&D/ commercialization investment, and makes liquidity management a persistent structural concern.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥10.95B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

Currently, no data Available

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 36,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.